Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2020

View Archived Issues

Data reported from ENCODE phase III

New phase I trial investigates JNJ-66525433 for ulcerative colitis

Roche and Genentech descirbe RIPK1 inhibitors

New STING agonists synthesized at Nankai University

Dana-Farber Cancer Institute patents DOT1L degraders

Vertex Pharmaceuticals discovers sodium channel protein type 10 subunit alpha blockers

GTPase KRAS G12C inhibitors identified described by Mirati Therapeutics and Array BioPharma

Src SH3 domain: an antithrombotic target without compromising homeostasis

European Commission approves Piqray for HR+/HER- breast cancer with PIK3CA mutation

FDA clears IND for phase I study of recombinant IAP SYN-020

J&J initiates first-in-human study with Ad26.COV2.S vaccine candidate against SARS-COV-2

Phase Ib data with Xeris' XP-0863 support progression to phase III for epilepsy

[18F]SMBT-1 shows promise for imaging astrogliosis in Alzheimer's disease

Phase III EMPEROR-Reduced trial of empagliflozin in HFrEF meets primary endpoint

Terns reports phase I data on TERN-201 for NASH

Cynata reports 2-year data from phase I study of CYP-001 in acute GvHD

Lexicon focuses on LX-9211, sells Xermelo

CDH12 identified as biomarker of kidney injury in patients with posterior urethral valves

Trillium advances dose escalation in phase Ib trial of TTI-621 in CTCL

FDA approves Tecentriq with Cotellic and Zelboraf for BRAF V600 mutation-positive advanced melanoma

Organoid-based drug screening unveils the role of menin-HIF axis in endometrial cancers

Clinical evaluation of [18F]EKZ-001 PET radiotracer to quantify HDAC6 brain expression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...